VCEL Vericel Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care markets
• • New product launch: MACI Arthro arthroscopic delivery system approved August 2024 and commercially available Q3 2024 with custom instruments
• • Strategic shift: expanded target surgeon base from 5,000 to 7,000 to include high-volume arthroscopic knee cartilage repair surgeons
• • Notable metric: MACI commercial team expanded by ~30% in late 2025 to support growth initiatives
• • Unique fact: Initiated MASCOT clinical trial in Q4 2025, first randomized study of MACI for ankle cartilage defects (osteochondral lesion of the talus)

Risk Factors

• • Regulatory risk: potential penalties from FDA or state agencies for off-label promotion or anti-kickback/anti-bribery law violations
• • Geopolitical risk: supply disruption of NexoBrid due to Middle East conflicts or China-Taiwan tensions, impacting commercial success
• • Operational risk: dependency on third-party manufacturer Matricel GmbH for critical components of MACI/Epicel cell manufacturing
• • Market disruption risk: competitive pressure from emerging artificial intelligence technologies affecting product innovation and adoption
• • Financial risk: key-person dependency on senior manufacturing, quality, and management personnel critical to ongoing operations

Management Discussion & Analysis

• • Revenue not explicitly stated, but sales volume increase indicated by accounts receivable growth and higher net income $16.5M in 2025 vs $10.4M in 2024
• • Net income $16.5M (2025), operating expenses include $38.8M stock compensation, no explicit margin % reported
• • No segment breakdown provided for best/worst performing segments
• • Operating cash flow $51.9M (2025) vs $58.2M (2024); investing cash outflows $44M net in 2025 vs $79M in 2024; financing cash inflows $7.1M (2025) vs $19M (2024) from stock option exercises less tax withholdings
• • Management expects current liquidity (cash + investments + borrowing capacity) sufficient for 12+ months; risks include R&D pace, clinical trials, patent costs, manufacturing capacity, acquisitions, and macroeconomic factors

What are the latest VCEL SEC filings in 2026?

Vericel Corp (VCEL) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did VCEL file its most recent 10-K annual report?

Vericel Corp (VCEL) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view VCEL 10-Q quarterly reports?

Vericel Corp (VCEL)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every VCEL 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has VCEL filed recently?

Vericel Corp (VCEL)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find VCEL insider trading activity (Form 4)?

SignalX aggregates every VCEL Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does VCEL file with the SEC?

Vericel Corp (VCEL) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new VCEL filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Vericel Corp (VCEL).

What is VCEL's SEC CIK number?

Vericel Corp (VCEL)'s SEC CIK (Central Index Key) number is 887359. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 887359 to look up all VCEL filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find VCEL return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Vericel Corp (VCEL) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.